Upgrade to SI Premium - Free Trial

Bayer AG (BAYRY)

10.15 -0.15 (1.46%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Bayer names new consumer health division leaders to accelerate growth June 8, 2026 8:00 AM - StreetInsider Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth June 8, 2026 8:00 AM - BizWire Bayer's KERENDIA shows kidney benefits in non-diabetic patients June 5, 2026 6:41 AM - StreetInsider Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disea June 5, 2026 6:40 AM - BizWire Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026 June 2, 2026 8:00 AM - BizWire Barclays on Bayer AG (BAYN:GR) (BAYRY): 'Conditional transfer of settlement to federal level adds noise' June 2, 2026 5:16 AM - StreetInsider ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial May 30, 2026 5:24 PM - BizWire UBS Reiterates Buy Rating on Bayer AG (BAYN:GR) (BAYRY) May 28, 2026 11:06 AM - StreetInsider Morgan Stanley continues to see "material upside" in this big pharma stock May 26, 2026 4:00 PM - StreetInsider Bayer to present cancer trial data at ASCO 2026 meeting May 21, 2026 8:00 AM - StreetInsider ASCO 2026: Bayer to Present New Data Across Oncology Portfolio May 21, 2026 8:00 AM - BizWire Bayer's KERENDIA gets FDA priority review for type 1 diabetes treatment May 21, 2026 2:30 AM - StreetInsider Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease May 21, 2026 2:30 AM - BizWire Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR50 at Barclays May 19, 2026 5:04 AM - StreetInsider FDA grants priority review for Bayer's asundexian stroke drug May 19, 2026 2:30 AM - StreetInsider Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack May 19, 2026 2:30 AM - BizWire FDA grants priority review for Bayer's HYRNUO lung cancer application May 18, 2026 8:41 AM - StreetInsider U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer May 18, 2026 8:41 AM - BizWire AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer May 15, 2026 11:10 AM - BizWire Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement May 15, 2026 9:01 AM - BizWire Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities May 13, 2026 9:04 AM - BizWire Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis May 7, 2026 2:30 AM - BizWire Bayer to acquire Perfuse Therapeutics for up to $2.45 billion May 6, 2026 2:30 AM - StreetInsider Bayer to acquire Perfuse Therapeutics for up to $2.45 billion May 6, 2026 2:30 AM - StreetInsider Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline May 6, 2026 2:30 AM - BizWire New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing April 29, 2026 8:00 AM - BizWire Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian April 29, 2026 8:00 AM - BizWire UBS Reiterates Buy Rating on Bayer AG (BAYN:GR) (BAYRY) April 28, 2026 2:23 AM - StreetInsider Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR43 at Deutsche Bank April 16, 2026 2:32 AM - StreetInsider Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class April 15, 2026 4:33 PM - BizWire UBS Reiterates Buy Rating on Bayer AG (BAYN:GR) (BAYRY) April 13, 2026 6:04 AM - StreetInsider Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential March 31, 2026 11:30 AM - BizWire Bayer AG (BAYN:GR) (BAYRY) PT Lowered to EUR49 at Kepler Cheuvreux March 31, 2026 3:17 AM - StreetInsider Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative March 26, 2026 11:30 AM - BizWire Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris March 26, 2026 9:55 AM - BizWire Bayer Crop Science Launches 2026 Opportunity Scholarship Program March 16, 2026 11:00 AM - BizWire UBS Upgrades Bayer AG (BAYN:GR) (BAYRY) to Buy March 16, 2026 3:59 AM - StreetInsider KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease March 16, 2026 3:30 AM - BizWire Bayer AG (BAYN:GR) (BAYRY) PT Lowered to EUR53 at Morgan Stanley March 11, 2026 5:30 AM - StreetInsider Full Article List